Form 4: Fulgent Genetics' Chief Scientific Officer Gao Hanlin Reports Stock Transaction

Sentiment:

SEC Form 4 Filing


Gao Hanlin, Chief Scientific Officer of Fulgent Genetics, reports the disposal of 111 shares of common stock to cover tax obligations.

Summary

  • On July 30, 2024, Gao Hanlin, the Chief Scientific Officer of Fulgent Genetics, disposed of 111 shares of common stock.
  • The transaction was executed to satisfy tax withholding obligations related to the vesting of restricted stock units.
  • The shares were sold at a price of $23.95 per share.
  • Following the transaction, Gao Hanlin beneficially owns 925,123 shares of Fulgent Genetics common stock.

Sentiment

Score: 5

Explanation: This is a neutral report of a routine stock transaction related to tax obligations. It doesn't indicate positive or negative sentiment about the company's performance.

Industry Context

This is a routine Form 4 filing related to executive compensation and tax obligations, common in publicly traded companies.

Key Dates

DateDescription
April 30, 2021Date of grant of restricted stock units to Gao Hanlin.
May 3, 2021Date Form 4 was filed reporting the grant of restricted stock units.
July 30, 2024Date of the stock transaction (disposal of shares).
August 01, 2024Date of signature on the Form 4 filing.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.